L
Laure Malinge
Publications - 6
Citations - 104
Laure Malinge is an academic researcher. The author has contributed to research in topics: Pomalidomide & Internal medicine. The author has an hindex of 3, co-authored 3 publications receiving 33 citations.
Papers
More filters
Journal ArticleDOI
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis
Meletios A. Dimopoulos,Xavier Leleu,Philippe Moreau,Paul G. Richardson,Anna Marina Liberati,Simon J. Harrison,H. Miles Prince,Enrique M. Ocio,Sylvie Assadourian,Frank Campana,Laure Malinge,Dorothée Semiond,Helgi van de Velde,Kwee Yong +13 more
TL;DR: The addition of Isa to Pd improved PFS, ORR and renal response rates, and Isa pharmacokinetics were comparable between the subgroups, suggesting no need for dose adjustment in patients with RI.
Journal ArticleDOI
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.
Paul G. Richardson,Aurore Perrot,Jesús F. San Miguel,Meral Beksac,Ivan Spicka,Xavier Leleu,Fredrik Schjesvold,Philippe Moreau,Meletios A. Dimopoulos,Jeffrey Shang Yi Huang,Jiri Minarik,Michele Cavo,H. Miles Prince,Laure Malinge,Franck Dubin,Helgi J. K. Van De Velde,Kenneth C. Anderson +16 more
TL;DR: The ICARIA-MM study showed significant improvement in progression-free survival with addition of isatuximab to pomalidomide-dexamethasone in relapsed and refractory multiple myeloma as discussed by the authors .
Journal ArticleDOI
Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients with Renal Impairment: Ikema Subgroup Analysis
Marcelo Capra,Thomas G. Martin,Philippe Moreau,Ross I. Baker,Ludek Pour,Chang-Ki Min,Xavier Leleu,Mohamad Mohty,Marta Segura,Mehmet Turgut,Richard Leblanc,Marie-Laure Risse,Laure Malinge,Sandrine Schwab,Meletios A. Dimopoulos +14 more
TL;DR: IKEMA was a randomized, open-label, multicenter, Phase 3 study that demonstrated the benefit of adding Isa to carfilzomib (K) plus d vs Kd in pts with relapsed MM, and was classified as durable if lasting ≥60 days.
Journal ArticleDOI
Effect of isatuximab plus pomalidomide/dexamethasone on renal impairment in relapsed/refractory multiple myeloma: ICARIA-MM study subgroup analysis
Meletios A. Dimopoulos,Xavier Leleu,Philippe Moreau,Michel Attal,Paul G. Richardson,Anna Marina Liberati,Simon J. Harrison,H. Miles Prince,Enrique M. Ocio,Sylvie Assadourian,Frank Campana,Laure Malinge,Helgi van de Velde,Kwee Yong +13 more
Journal ArticleDOI
Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies
Paul G. Richardson,Aurore Perrot,Jesús F. San Miguel,Meral Beksac,Ivan Spicka,Xavier Leleu,Fredrik Schjesvold,Philippe Moreau,Meletios A. Dimopoulos,Jeffrey Shang Yi Huang,Jiri Minarik,Michele Cavo,H. Miles Prince,Sandrine Macé,Laure Malinge,Franck Dubin,Mony Chenda Morisse,Kenneth C. Anderson +17 more
TL;DR: In this article , an anti-CD38 monoclonal antibody (Isatuximab) was used in combination with pomalidomide and dexamethasone (Pd) for patients with relapsed and refractory multiple myeloma (RRMM) who have received at least 2 prior treatments.